<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article  PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "http://dtd.nlm.nih.gov/publishing/3.0/journalpublishing3.dtd"><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="3.0" xml:lang="en" article-type="research article"><front><journal-meta><journal-id journal-id-type="publisher-id">OJRA</journal-id><journal-title-group><journal-title>Open Journal of Rheumatology and Autoimmune Diseases</journal-title></journal-title-group><issn pub-type="epub">2163-9914</issn><publisher><publisher-name>Scientific Research Publishing</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.4236/ojra.2024.142006</article-id><article-id pub-id-type="publisher-id">OJRA-132068</article-id><article-categories><subj-group subj-group-type="heading"><subject>Articles</subject></subj-group><subj-group subj-group-type="Discipline-v2"><subject>Medicine&amp;Healthcare</subject></subj-group></article-categories><title-group><article-title>
 
 
  Serum Immunoglobulin Concentrations in Juvenile Idiopathic Arthritis Cases during Active and Inactive Disease States
 
</article-title></title-group><contrib-group><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Sajib</surname><given-names>Muhammad Rayhan</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Kamrul</surname><given-names>Laila</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Shahana</surname><given-names>A. Rahman</given-names></name><xref ref-type="aff" rid="aff3"><sup>3</sup></xref></contrib></contrib-group><aff id="aff3"><addr-line>Department of Paediatrics (on PRL) Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh</addr-line></aff><aff id="aff2"><addr-line>Department of Paediatrics, Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh</addr-line></aff><aff id="aff1"><addr-line>Consultant (Paediatrics), Kalkini Upazila Health Complex, Dhaka, Bangladesh</addr-line></aff><pub-date pub-type="epub"><day>27</day><month>03</month><year>2024</year></pub-date><volume>14</volume><issue>02</issue><fpage>49</fpage><lpage>59</lpage><history><date date-type="received"><day>20,</day>	<month>January</month>	<year>2024</year></date><date date-type="rev-recd"><day>24,</day>	<month>March</month>	<year>2024</year>	</date><date date-type="accepted"><day>27,</day>	<month>March</month>	<year>2024</year></date></history><permissions><copyright-statement>&#169; Copyright  2014 by authors and Scientific Research Publishing Inc. </copyright-statement><copyright-year>2014</copyright-year><license><license-p>This work is licensed under the Creative Commons Attribution International License (CC BY). http://creativecommons.org/licenses/by/4.0/</license-p></license></permissions><abstract><p>
 
 
  <b>Background: </b>
  Juvenile idiopathic arthritis (JIA) is the most common rheumatic disease in
   
  children. Both the humoral and cell mediated immunities are involved in
   the
   pathogenesis of JIA. It is reported that overall immunoglobulin levels in JIA patients are significantly higher than their control during the active state of disease. <b>Methodology: </b>This prospective observational study was conducted over a period of 18 months All the newly diagnosed oligo-articular and poly-articular JIA patients having active disease were included by purposive sampling. Data were collected by a semi-structured predesigned questionnaire. <b>Result: </b>Most of the study subjects (57.6%) belonged to age group &gt;
   
  3 - 9 years. Oligo JIA was diagnosed in 66.7% and poly JIA in 33.3%
   
  of JIA children. The difference in
   
  mean (&#177;SD) ESR (33.52
   
  &#177;
   
  21.29 and 15.09
   
  &#177;
   
  7.71 mm in 1st hour) at active and inactive states
   
  was highly significant. Mean (&#177;SD) difference of IgG, IgM and IgA in active and inactive states
   
  of disease were highly significant. <b>Conclusion: </b>Higher and abnormal levels of immunoglobulin (IgG, IgM, and IgA) were present among JIA patients
   
  in active disease state which became normal during inactive disease state after treatment.
 
</p></abstract><kwd-group><kwd>JIA</kwd><kwd> Oligoarticular JIA</kwd><kwd> Polyarticular JIA</kwd><kwd> Immunoglobulins</kwd><kwd> Acitive Disease</kwd><kwd> Inactive Disease</kwd></kwd-group></article-meta></front><body><sec id="s1"><title>1. Introduction</title><p>Juvenile idiopathic arthritis (JIA) is the most common rheumatic disease in children. The global prevalence of JIA has been estimated to range from 3.8 to 400/100,000 with an incidence of 1.6 to 23/100,000 [<xref ref-type="bibr" rid="scirp.132068-ref1">1</xref>] . In the United Kingdom, the age-standardized prevalence rate in 2018 was 43.5 per 100,000 [<xref ref-type="bibr" rid="scirp.132068-ref2">2</xref>] . The exact incidence and prevalence of JIA is not known in our country. A pilot study in a semi-urban area of Bangladesh showed the prevalence of JIA as 60.5 per 100,000 [<xref ref-type="bibr" rid="scirp.132068-ref3">3</xref>] .</p><p>JIA is an immune mediated disease. Alterations of the immune system have been documented in JIA [<xref ref-type="bibr" rid="scirp.132068-ref4">4</xref>] . Both the humoral and cell mediated immunities are involved in the pathogenesis of JIA. T lymphocytes play a central role in the release of proinflamatory cytokines (TNF, IL1 and IL6). Evidences of abnormalities in the humoral immune system include increased presence of autoantibodies (especially antinuclear antibodies), increased serum immunoglobulins, presence of circulating immune complexes and complement activation [<xref ref-type="bibr" rid="scirp.132068-ref4">4</xref>] . The association of RF (Rheumatoid factor-antibodies reactive to IgG) with the disease also suggests an immune mechanism. It is reported that overall immunoglobulin levels in JIA patients are significantly higher than their control and JIA patients with growth failure had higher IgM, IgA and IgG levels in comparison with patients without growth failure [<xref ref-type="bibr" rid="scirp.132068-ref5">5</xref>] . Immunodeficiency states such as selective IgA deficiency and hypogammaglobulinemia are also reported as statistically more frequent in children with chronic arthritis in [<xref ref-type="bibr" rid="scirp.132068-ref6">6</xref>] .</p><p>Initiation of the JIA pathophysiological cascade includes abnormal activation of T-cells, B-cells, natural killer (NK) cells, dendritic cells (DC), macrophages and neutrophils and the production of pro-inflammatory mediators that cause joint destruction and systemic complications. Oligoarticular and polyarticular JIA are characterized by auto-reactive antigen-specific T-cells and high titres of autoantibodies, and typically show strong associations with MHC class II alleles. Breakdown of immunologic self-tolerance involves MHC class II alleles suggesting a pivotal role for CD4+ T helper (Th) cells [<xref ref-type="bibr" rid="scirp.132068-ref7">7</xref>] .</p><p>Inflammation is considered to be a consequence of a disrupted balance between pro-inflammatory Th1/Th17 and anti-inflammatory regulatory T-cells (Treg) [<xref ref-type="bibr" rid="scirp.132068-ref8">8</xref>] . Systemic JIA (sJIA) cases are suggested to have an auto inflammatory pathology with different pathogenesis [<xref ref-type="bibr" rid="scirp.132068-ref9">9</xref>] . In enthesitis related arthritis (ERA) there is more genetic susceptibility rather than immunological predisposition. The pathogenesis of ERA is also different from other types of JIA [<xref ref-type="bibr" rid="scirp.132068-ref10">10</xref>] .</p><p>The goal of treatment in JIA patients is to bring the disease activity into remission. When the patient has inactive disease state, the inflammatory process is also stopped and immunological markers come down to normal concentration [<xref ref-type="bibr" rid="scirp.132068-ref4">4</xref>] .</p><p>No study so far has been done to measure immunoglobulin (IgG, IgM, and IgA) levels in JIA patients in our country. This study was carried out with the objective of assessing the immunoglobulin levels and comparing these levels during active and inactive states of oligo and polyarticular JIA patients in a tertiary care hospital in Bangladesh.</p></sec><sec id="s2"><title>2. Materials AND Methods</title><p>It was a prospective observational study, conducted in a pediatric rheumatology clinic, Department of Pediatrics and Department of Microbiology and Immunology, Bangabandhu Sheikh Mujib Medical University (BSMMU).</p><p>The study period was 18 months (From January 2016 to June 2017). All the newly diagnosed oligo-articular and poly-articular juvenile idiopathic arthritis patients, having active disease attending paediatric rheumatology clinic and inpatient department of paediatrics, BSMMU during the study period were included by purposive sampling.</p><p>Because of different pathogenesis, systemic onset JIA (sJIA) and ERA cases were not included in this study.</p><p>JIA patients, not having active disease or in remission and patients unwilling to give consent were excluded from the study. JIA patients likely to have confounding factors including severe malnutrition, steroid therapy, immunosuppressive therapy or chronic co-morbidities were excluded from the study. Ethical clearance was taken from the Institutional Review Board (IRB) of BSMMU before starting the study.</p><p>Data were collected by a semi-structured predesigned questionnaire developed in Bangla (Bengali). Prior pre-testing was done on 10 cases to test the reliability and validity. Later on, the questionnaire was translated into English by competent persons. Both the Bangla and English versions were used according to requirements but data entry and calculation were done in English.</p><p>The patients and their parents were informed about the study design and its objectives. They were explained that there would be no physical or social risk for the participants except minor pain during venipuncture. They were also informed about the freedom to participate or not to participate at any time. No incentive was given for participation.</p><sec id="s2_1"><title>2.1. Study Procedure</title><p>Sample Size calculation</p><p>As an observational study the sample size was calculated in following manner:</p><p>sample size n = [ ( z α + z β ) 2 &#215; ( δ 1 2 + δ 2 2 ) ] / ( μ 1 − μ 2 ) 2 [<xref ref-type="bibr" rid="scirp.132068-ref11">11</xref>] .</p><p>z<sub>α</sub> = Confidence level 95% = 1.96</p><p>z<sub>β</sub> = Standard normal distribution of a definite power; 0.85</p><p>&#181;<sub>1</sub>= Mean of one group; 1790</p><p>&#181;<sub>2</sub>= Mean of other group; 1570</p><p>δ<sub>1</sub> = SD of one group; 535</p><p>δ<sub>2</sub> = SD of other group; 360</p><p>n = { ( 1.96 + 0.85 ) 2 &#215; ( 535 2 + 360 2 ) } / ( 1790 − 1570 ) 2 = 68</p><p>A total of consecutive 68 newly diagnosed cases of poly and oligo-JIA cases fulfilling inclusion criteria were included in the study. But two poly-JIA patients did not come for regular follow-up. So analysis of 66 patients was done in the study. After diagnosis of JIA cases in pediatric rheumatology follow up clinic, the pre-designed questionnaire was completed for each patient by interviewing them or their parents after taking their written consent. Information was also obtained from their medical records. Variables included patients’ characteristics including age (in years), gender, diagnosis (sub-types), and duration of disease (in months) and biochemical parameters of blood sample during active (at initial visit) and inactive diseases state (at 6 months, 9 months or 12 months follow up, whenever the JIA cases became inactive). All the JIA patients were treated by the pediatric rheumatologists according to standard protocol with the objective of bringing the disease into an inactive state. Diseases activity was measured by Wallace criteria 2004 [<xref ref-type="bibr" rid="scirp.132068-ref12">12</xref>] . Follow up of patients was done at 3, 6, 9 and 12 months.</p></sec><sec id="s2_2"><title>2.2. Collection of Blood</title><p>With all aseptic precautions 2 ml venous blood sample was drawn from the ante-cubital vein. The blood sample was transferred immediately into a coded test tube without any anticoagulant agents and kept for investigation in the Microbiology and Immunology department and preserved in ultra-freezer at minus 20 degrees centigrade until the analysis.</p><p>Quantitative measurements of serum immunoglobulins IgG, IgA and IgM were done via nephelometry in the Department of microbiology and immunology, BSMMU. All the investigations were done at the time of diagnosis during active diseases state and again repeated when disease state became inactive during follow up at 6 months, 9 months or 12 months.</p><p>All the investigation result of immunoglobulin was given in gm/L from the Department of Microbiology and Immunology, BSMMU. As the standard reference value is given in mg/dl, the supplied results were converted to mg/dL. In addition as the value was given in the adult range, the values were also converted into pediatric range by using the software provided by: http://www.endmemo.com/medical/unitconvert/Immunoglobulin_G.php.</p></sec><sec id="s2_3"><title>2.3. Normal Immunoglobulin Concentration in Adult [<xref ref-type="bibr" rid="scirp.132068-ref13">13</xref>]</title><p>Conversion of immunoglobulin concentration from reference range was done in following way:</p><p>Age 1 - 3 years: 453 - 916 mg/dL</p><p>Conversion to gm/L, dividing by 100: 4.53 - 9.16 gm/L</p><p>http://www.endmemo.com/medical/unitconvert/Immunoglobulin_G.php reference</p><p>All the parameters were compared between active and inactive diseases state. All statistical calculations were done using the statistical software SPSS 21.0. The Chi-square test or t-test was applied to evaluate the association between the variables when indicated. The results were presented in Tables, figures &amp; diagrams. P-value less than 0.05 were considered as significant at a 95% confidence interval for the correlation.</p></sec></sec><sec id="s3"><title>3. Result</title><p>Among the total 66 JIA children, 39.4% were male and 60.6% were female. Mean (&#177;SD) age was 7.97 &#177; 3.72 (range 2 - 14) years. Most of the study subjects (57.6%) belonged to age group &gt; 3 - 9 years, followed by &gt; 9 years (36.4%). Oligo-JIA was diagnosed in 66.7% and poly-JIA in 33.3% of JIA children (<xref ref-type="table" rid="table1">Table 1</xref>).</p><p>Mean (&#177;SD) platelet count was 413.45 &#177; 135.46 in the active state and 350.97 &#177; 100.34 10<sup>9</sup>/L in the inactive state, respectively. The difference was significant (P &lt; 0.05). The difference in mean (&#177;SD) ESR at active state (33.52 &#177; 21.29) and inactive state (15.09 &#177; 7.71 mm in 1st hour) was also highly significant (<xref ref-type="table" rid="table2">Table 2</xref>).</p><p><xref ref-type="table" rid="table3">Table 3</xref> shows immunoglobulin concentrations in active and inactive states of all JIA patients (n = 66). Mean (&#177;SD) difference of IgG at active state (13.04 &#177; 4.41) and inactive state (9.88 &#177; 2.31 g/L) was highly significant (P &lt; 0.001). Mean (&#177;SD) difference of IgM at active state (3.25 &#177; 1.80) and inactive state (1.82 &#177; 0.88 g/L) of disease was highly significant (P &lt; 0.001). Mean (&#177;SD) difference of IgA was also highly significant (<xref ref-type="table" rid="table3">Table 3</xref>).</p><p><xref ref-type="fig" rid="fig1">Figure 1</xref> shows the status of immunoglobulin concentrations of oligo-JIA patients in an active and inactive state of disease (n = 44). Mean (&#177;SD) IgG was 11.95 &#177; 4.58 in the active state and 9.48 &#177; 2.58 g/L in inactive state of disease. The difference was highly significant (P &lt; 0.01). The mean difference in IgM concentration between active and inactive disease was also highly significant (P &lt; 0.001). Mean (&#177;SD) IgA was 3.03 &#177; 1.36 in an active state and 1.31 &#177; 0.54 g/L in inactive state of the disease and the difference was highly significant (P &lt; 0.001).</p><p><xref ref-type="fig" rid="fig2">Figure 2</xref> shows status of immunoglobulin concentrations of poly-JIA patients</p><table-wrap id="table1" ><label><xref ref-type="table" rid="table1">Table 1</xref></label><caption><title> Gender, age and types of JIA among the study population (n = 66)</title></caption><table><tbody><thead><tr><th align="center" valign="middle" >Parameters</th><th align="center" valign="middle" >Mean &#177; SD</th><th align="center" valign="middle" >No. (%)</th></tr></thead><tr><td align="center" valign="middle" >Gender</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >Male</td><td align="center" valign="middle" ></td><td align="center" valign="middle" >26 (39.4)</td></tr><tr><td align="center" valign="middle" >Female</td><td align="center" valign="middle" ></td><td align="center" valign="middle" >40 (60.6)</td></tr><tr><td align="center" valign="middle" >Age (in years)</td><td align="center" valign="middle" >7.97 &#177; 3.72</td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >1 - 3</td><td align="center" valign="middle" ></td><td align="center" valign="middle" >4 (6.1)</td></tr><tr><td align="center" valign="middle" >&gt; 3 - 6</td><td align="center" valign="middle" ></td><td align="center" valign="middle" >20 (30.30)</td></tr><tr><td align="center" valign="middle" >&gt; 6 - 9</td><td align="center" valign="middle" ></td><td align="center" valign="middle" >18 (27.27)</td></tr><tr><td align="center" valign="middle" >&gt;9</td><td align="center" valign="middle" ></td><td align="center" valign="middle" >24 (36.4)</td></tr><tr><td align="center" valign="middle" >Diagnosis of JIA</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >Oligo-JIA</td><td align="center" valign="middle" ></td><td align="center" valign="middle" >44 (66.7)</td></tr><tr><td align="center" valign="middle" >Poly-JIA</td><td align="center" valign="middle" ></td><td align="center" valign="middle" >22 (33.3)</td></tr></tbody></table></table-wrap><table-wrap id="table2" ><label><xref ref-type="table" rid="table2">Table 2</xref></label><caption><title> Laboratory parameters of JIA cases in active and inactive states of patients (n = 66)</title></caption><table><tbody><thead><tr><th align="center" valign="middle" >Parameter</th><th align="center" valign="middle" >Active state</th><th align="center" valign="middle" >Inactive state</th><th align="center" valign="middle" >P value</th></tr></thead><tr><td align="center" valign="middle" >(Mean &#177; SD)</td><td align="center" valign="middle" >(Mean &#177; SD)</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >Hb (g/dl)</td><td align="center" valign="middle" >10.93 &#177; 1.69</td><td align="center" valign="middle" >11.36 &#177; 0.93</td><td align="center" valign="middle" >0.098<sup>ns</sup></td></tr><tr><td align="center" valign="middle" >TC (10<sup>9</sup>/L)</td><td align="center" valign="middle" >7.00 &#177; 3.22</td><td align="center" valign="middle" >9.06 &#177; 2.74</td><td align="center" valign="middle" >0.981<sup>ns</sup></td></tr><tr><td align="center" valign="middle" >WBC DC-N (%)</td><td align="center" valign="middle" >55.82 &#177; 14.55</td><td align="center" valign="middle" >55.58 &#177; 10.41</td><td align="center" valign="middle" >0.925<sup>ns</sup></td></tr><tr><td align="center" valign="middle" >WBC DC-L (%)</td><td align="center" valign="middle" >36.85 &#177; 14.71</td><td align="center" valign="middle" >32.36 &#177; 12.07</td><td align="center" valign="middle" >0.160<sup>ns</sup></td></tr><tr><td align="center" valign="middle" >Platelet (10<sup>9</sup>/L)</td><td align="center" valign="middle" >413.45 &#177; 135.46</td><td align="center" valign="middle" >350.97 &#177; 100.34</td><td align="center" valign="middle" >0.021<sup>*</sup></td></tr><tr><td align="center" valign="middle" >ESR (1st hr)</td><td align="center" valign="middle" >33.52 &#177; 21.29</td><td align="center" valign="middle" >15.09 &#177; 7.71</td><td align="center" valign="middle" >0.0001<sup>***</sup></td></tr></tbody></table></table-wrap><p>Paired student’s “t” test.</p><p>ns = Not significant.</p><p>* = Significant at P &lt; 0.05.</p><p>*** = Significant at P &lt; 0.001.</p><table-wrap id="table3" ><label><xref ref-type="table" rid="table3">Table 3</xref></label><caption><title> Status of immunoglobulin concentrations in active and inactive state of disease in JIA patients (n = 66)</title></caption><table><tbody><thead><tr><th align="center" valign="middle" >Parameter</th><th align="center" valign="middle" >Active state</th><th align="center" valign="middle" >Inactive state</th><th align="center" valign="middle" >P value</th></tr></thead><tr><td align="center" valign="middle" >(Mean &#177; SD)</td><td align="center" valign="middle" >(Mean &#177; SD)</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >IgG (g/L)</td><td align="center" valign="middle" >13.04 &#177; 4.41</td><td align="center" valign="middle" >9.88 &#177; 2.31</td><td align="center" valign="middle" >0.0001<sup>***</sup></td></tr><tr><td align="center" valign="middle" >IgM (g/L)</td><td align="center" valign="middle" >3.25 &#177; 1.80</td><td align="center" valign="middle" >1.82 &#177; 0.88</td><td align="center" valign="middle" >0.0001<sup>***</sup></td></tr><tr><td align="center" valign="middle" >IgA (g/L)</td><td align="center" valign="middle" >3.29 &#177; 1.18</td><td align="center" valign="middle" >1.34 &#177; 0.47</td><td align="center" valign="middle" >0.0001<sup>***</sup></td></tr></tbody></table></table-wrap><p>Paired student’s “t” test.</p><p>*** = Significant at P &lt; 0.001.</p><p>in active and inactive state of disease (n = 22). Differences of mean IgG, IgM and IgA between active and inactive state of disease were highly significant (P &lt; 0.001).</p></sec><sec id="s4"><title>4. Discussion</title><p>Juvenile idiopathic arthritis (JIA) is a chronic inflammatory disease affecting hundreds of thousands of children worldwide. Advances in our understanding of the pathogenesis of JIA over the last two decades have revolutionized therapy, reduced morbidity, and improved the quality of life for children with JIA [<xref ref-type="bibr" rid="scirp.132068-ref14">14</xref>] . Although the disease’s etiology is unknown, disturbances in innate and adaptive immune responses have been implicated. B cells may have important roles in JIA pathogenesis through autoantibody production, antigen presentation, cytokine release and/or T cell activation [<xref ref-type="bibr" rid="scirp.132068-ref15">15</xref>] .</p><p>Globally, approximately 3 million children and young adults are estimated to suffer from JIA. Girls were consistently found to be at a higher risk than boys, and oligoarticular subtype was found to be predominant [<xref ref-type="bibr" rid="scirp.132068-ref1">1</xref>] .</p><p>Hematologic abnormalities generally reflect the extent of the inflammatory disease. Useful laboratory investigations include blood count (CBC) and inflammatory markers like erythrocyte sedimentation rate (ESR) [<xref ref-type="bibr" rid="scirp.132068-ref16">16</xref>] . In general, ESR is a useful measure of active disease in a child with JIA [<xref ref-type="bibr" rid="scirp.132068-ref12">12</xref>] . One of the effects of pro-inflammatory cytokines produced in response to systemic inflammation in the liver is megakaryocyte stimulation and thus increases in the number of platelets in response to inflammation. This results in the production of larger and more reactive platelets [<xref ref-type="bibr" rid="scirp.132068-ref17">17</xref>] . In our study cases, ESR and platelet count were significantly higher in active diseases state and became normal in inactive disease states (p value &lt; 0.05). These findings were similar to previous studies [<xref ref-type="bibr" rid="scirp.132068-ref18">18</xref>] .</p><p>In our center, another study was conducted among JIA patients showing, higher mean neutrophil count and platelet count during the active state of the disease. Mean ESR and CRP were raised in all JIA patients at the active state which explains the strong association of CRP and ESR with JIA disease activity [<xref ref-type="bibr" rid="scirp.132068-ref19">19</xref>] .</p><p>JIA is a complex autoimmune disease and its exact etiology is still unknown. But it is an established fact that a combination of genetic susceptibility and unknown environmental triggers leads to immune imbalance. T lymphocytes play a central role in the release of proinflamatory cytokines (TNF, IL1 and IL6). Evidence for abnormalities in the humoral immune system includes the increased presence of autoantibodies (especially antinuclear antibodies), increased serum immunoglobulins, the presence of circulating immune complexes, complement activation and association of RF (Rheumatoid factor-antibodies reactive to IgG) [<xref ref-type="bibr" rid="scirp.132068-ref4">4</xref>] .</p><p>The ultimate goal of treatment in JIA patients is to achieve remission, i.e. complete suppression of disease activity. When the active disease process is stopped and the patient has an inactive disease state, the inflammatory process is also stopped and immunological markers come down to normal concentration [<xref ref-type="bibr" rid="scirp.132068-ref20">20</xref>] .</p><p>In the present study, the concentrations of the serum immunoglobulins IgG, IgM, and IgA were determined in 66 JIA patients, where abnormalities (much higher concentration) of these Immunoglobulins were found in active state. These results were similar to previous studies [<xref ref-type="bibr" rid="scirp.132068-ref5">5</xref>] [<xref ref-type="bibr" rid="scirp.132068-ref21">21</xref>] . In the study done by Veys et al. it was found that there was the elevation of IgG and IgA levels but IgM level was normal in JIA cases in an active disease state [<xref ref-type="bibr" rid="scirp.132068-ref11">11</xref>] . Some studies also found elevations in serum IgG and selective depressions in serum IgA levels in active disease states [<xref ref-type="bibr" rid="scirp.132068-ref22">22</xref>] .</p><p>In the present study, significantly higher concentrations of IgG, IgA, and IgM were found in an active disease state, which became lower and normal during an inactive state. A study done by Rackham OJ et al. had shown similar results [<xref ref-type="bibr" rid="scirp.132068-ref23">23</xref>] . But a study done by Torre et al. found different results where, immunoglobulin concentration was low to normal range in inactive state but IgA concentration were still high in a number of patients [<xref ref-type="bibr" rid="scirp.132068-ref24">24</xref>] .</p><p>When the total JIA cases were subdivided into oligo articular and poly articular JIA group, it was found that among 44 oligo JIA patients, all the three immunoglobulin (IgG, IgM and IgA) concentration was significantly higher in active diseases state. These findings were comparable with previous studies [<xref ref-type="bibr" rid="scirp.132068-ref23">23</xref>] [<xref ref-type="bibr" rid="scirp.132068-ref24">24</xref>] .</p><p>Similarly, among 22 polyarticular JIA patients, it was found that the difference in IgG, IgM, and IgA concentration between active and inactive disease states was highly significant (P &lt; 0.001) which supports the findings of Rackham OJ et al. in 2002. However a study done by Davies K et al. showed that there was a decrease concentration of IgA in poly articular JIA in active disease state [<xref ref-type="bibr" rid="scirp.132068-ref25">25</xref>] .</p><p>In the present study IgG, IgM, IgA concentration significantly fell and became normal during inactive state of disease. Rackham OJ et al. found similar results whwre IgG, IgM and IgA concentration significantly fall in inactive disease state [<xref ref-type="bibr" rid="scirp.132068-ref23">23</xref>] . Torre ID et al. also found similar result [<xref ref-type="bibr" rid="scirp.132068-ref24">24</xref>] . It was expected that majority of the patients have abnormal concentration of immunoglobulins at presentation during the initial active diseases state which would become normal after treatment during inactive disease state. Our study results fulfilled the expectations. Determination of serum immunoglobulin concentration is of potential importance for understanding the pathogenesis involved in autoimmune and inflammatory disorders [<xref ref-type="bibr" rid="scirp.132068-ref26">26</xref>] .</p></sec><sec id="s5"><title>5. Conclusion</title><p>The study concluded that significantly higher and abnormal levels of immunoglobulin (IgG, IgM, and IgA) were present among JIA patients in active disease state which became normal during inactive disease state after treatment. Clinical implications of Immunoglobulin levels could be understood from this study. Measuring immunoglobulin levels may guide the disease progression or improvement and decisions regarding treatment.</p></sec><sec id="s6"><title>6. Recommendations</title><p>From the results and observation of this study, following recommendations may be made:</p><p>1) Further multicenter study should be done with larger sample size.</p><p>2) Immunoglobulin concentration value should be provided for pediatric age range from the Department of microbiology and immunology where investigations are done.</p></sec><sec id="s7"><title>7. Limitations of the Study</title><p>It was a single center study with short study period.</p></sec><sec id="s8"><title>Conflicts of Interest</title><p>The authors declare no conflicts of interest regarding the publication of this paper.</p></sec><sec id="s9"><title>Cite this paper</title><p>Rayhan, S.M., Laila, K. and Rahman, S.A. (2024) Serum Immunoglobulin Concentrations in Juvenile Idiopathic Arthritis Cases during Active and Inactive Disease States. Open Journal of Rheumatology and Autoimmune Diseases, 14, 49-59. https://doi.org/10.4236/ojra.2024.142006</p></sec></body><back><ref-list><title>References</title><ref id="scirp.132068-ref1"><label>1</label><mixed-citation publication-type="other" xlink:type="simple">Thierry, S., Fautrel, B., Lemelle, I. and Guillemin, F. (2014) Prevalence and Incidence of Juvenile Idiopathic Arthritis: A Systematic Review. Joint Bone Spine, 81, 112-117. https://doi.org/10.1016/j.jbspin.2013.09.003</mixed-citation></ref><ref id="scirp.132068-ref2"><label>2</label><mixed-citation publication-type="other" xlink:type="simple">Costello, R., McDonagh, J., Hyrich, K.L. and Humphreys, J.H. (2022) Incidence and Prevalence of Juvenile Idiopathic Arthritis in the United Kingdom, 2000-2018: Results from the Clinical Practice Research Datalink. Rheumatology, 61, 2548-2554. https://doi.org/10.1093/rheumatology/keab714</mixed-citation></ref><ref id="scirp.132068-ref3"><label>3</label><mixed-citation publication-type="other" xlink:type="simple">Azam, S., Dipti, T. and Rahman, S. (2012) Prevalence and Clinical Pattern of Juvenile Idiopathic Arthritis in a Semi-Urban Area of Bangladesh. International Journal of Rheumatic Diseases, 15, 116-120. https://doi.org/10.1111/j.1756-185X.2012.01703.x</mixed-citation></ref><ref id="scirp.132068-ref4"><label>4</label><mixed-citation publication-type="book" xlink:type="simple">Eveline, Y.W., Bryan, A.R. and Rabinovich, C.E. (2016) Juvenile Idiopathic Arthritis. In: Kliegman, R.M., Stanton, B.F., Schor, N.F., Geme, J.W.S. and Behrman, R.E., Eds., Nelson Textbook of Paediatrics, 20th Edition, Saunders, Philadelphia, 1160-1173.</mixed-citation></ref><ref id="scirp.132068-ref5"><label>5</label><mixed-citation publication-type="other" xlink:type="simple">Moradinejad, M., Rafati, A., Ardalan, M., Rabiei, M., Farghadan, M., Ashtiani, M.T., Pourpak, Z. and Moin, M. (2011) Prevalence of IgA Deficiency in Children with Juvenile Rheumatoid Arthritis. Iran Journal of Allergy, Asthma and Immunology, 10, 35-40.</mixed-citation></ref><ref id="scirp.132068-ref6"><label>6</label><mixed-citation publication-type="other" xlink:type="simple">Badcock, J., Clarke, S., Jones, P., Dawes, P. and Mattey, D. (2003) Abnormal IgA Levels in Patients with Rheumatoid Arthritis. Annals of Rheumatic Diseases, 62, 83-84. https://doi.org/10.1136/ard.62.1.83</mixed-citation></ref><ref id="scirp.132068-ref7"><label>7</label><mixed-citation publication-type="other" xlink:type="simple">De Silvestri, A., Capittini, C., Poddighe, D., Marseglia, G.L., Mascaretti, L., Bevilacqua, E., et al. (2017) HLA-DRB1 Alleles and Juvenile Idiopathic Arthritis: Diagnostic Clues Emerging from a Meta-Analysis. Autoimmunity Reviews, 16, 1230-1236. https://doi.org/10.1016/j.autrev.2017.10.007</mixed-citation></ref><ref id="scirp.132068-ref8"><label>8</label><mixed-citation publication-type="other" xlink:type="simple">Nistala, K., Moncrieffe, H., Newton, K.R., Varsani, H., Hunter, P. and Wedderburn, L.R. (2008) Interleukin-17-Producing T Cells Are Enriched in the Joints of Children with Arthritis, but Have a Reciprocal Relationship to Regulatory T Cell Numbers. Arthritis &amp; Rheumatology, 58, 875-887. https://doi.org/10.1002/art.23291</mixed-citation></ref><ref id="scirp.132068-ref9"><label>9</label><mixed-citation publication-type="other" xlink:type="simple">Mellins, E.D., Macaubas, C. and Grom, A.A. (2011) Pathogenesis of Systemic Juvenile Idiopathic Arthritis: Some Answers, More Questions. Nature Reviews Rheumatology, 7, 416-426. https://doi.org/10.1038/nrrheum.2011.68</mixed-citation></ref><ref id="scirp.132068-ref10"><label>10</label><mixed-citation publication-type="other" xlink:type="simple">Vander, S.M., Linden, H.A., Valkenburg, B.M. and DeJongh, A.C. (1984) The Risk of Developing Ankylosing Spondylitis in HLA-B27 Positive Individuals. A Comparison of Relatives of Spondylitis Patients with the General Population. Arthritis &amp; Rheumatology, 27, 241-249. https://doi.org/10.1002/art.1780270301</mixed-citation></ref><ref id="scirp.132068-ref11"><label>11</label><mixed-citation publication-type="other" xlink:type="simple">Veys, E.M. and Claessens, H.E. (1968) Serum Levels of IgG, IgM, and IgA in Rheumatoid Arthritis. Annals of Rheumatological Diseases, 27, 431-440. https://doi.org/10.1136/ard.27.5.431</mixed-citation></ref><ref id="scirp.132068-ref12"><label>12</label><mixed-citation publication-type="other" xlink:type="simple">Wallace, C., Ruperto, N. and Giannini, E. (2004) Preliminary Criteria for Clinical Remission for Select Categories of Juvenile Idiopathic Arthritis. The Journal of Rheumatology, 31, 2290-2294.</mixed-citation></ref><ref id="scirp.132068-ref13"><label>13</label><mixed-citation publication-type="other" xlink:type="simple">Jolliff, C.R., et al. (1982) Reference Values for Serum IgG, IgA, IgM, C3, and C4 as Determined by Rate Nephelometry. Clinical Chemistry, 28, 126-128. https://doi.org/10.1093/clinchem/28.1.126</mixed-citation></ref><ref id="scirp.132068-ref14"><label>14</label><mixed-citation publication-type="other" xlink:type="simple">Harrold, L.R., Salman, C., Shoor, S., Curtis, J.R., Asgari, M.M., Gelfand, J.M., et al. (2013) Incidence and Prevalence of Juvenile Idiopathic Arthritis among Children in a Managed Care Population, 1996-2009. The Journal of Rheumatology, 40, 1218-1225. https://doi.org/10.3899/jrheum.120661</mixed-citation></ref><ref id="scirp.132068-ref15"><label>15</label><mixed-citation publication-type="other" xlink:type="simple">Moura, R.A. and Fonseca, J.E. (2022) B Cells on the Stage of Inflammation in Juvenile Idiopathic Arthritis: Leading or Supporting Actors in Disease Pathogenesis? Frontiers in Medicine (Lausanne), 9, Article ID: 851532.</mixed-citation></ref><ref id="scirp.132068-ref16"><label>16</label><mixed-citation publication-type="other" xlink:type="simple">Gilliam, B.E., Chauhan, A.K. and Low, J.M. (2008) Measurement of Biomarkers in Juvenile Idiopathic Arthritis Patients and Their Significant Association with Disease Severity: A Comparative Study. Clinical and Experimental Rheumatology, 6, 492-497.</mixed-citation></ref><ref id="scirp.132068-ref17"><label>17</label><mixed-citation publication-type="other" xlink:type="simple">Vakili, M., Ziaee, V., Moradinejad, M.H., Raeeskarami, S.R., Kompani, F. and Rahamooz, T. (2016) Changes of Platelet Indices in Juvenile Idiopathic Arthritis in Acute Phase and after Two Months Treatment. Iranian Journal of Pediatrics, 26, E5006. https://doi.org/10.5812/ijp.5006</mixed-citation></ref><ref id="scirp.132068-ref18"><label>18</label><mixed-citation publication-type="other" xlink:type="simple">Kim, K.H. and Dong, S.K. (2010) Juvenile Idiopathic Arthritis: Diagnosis and Differential Diagnosis. Korean Journal of Pediatrics, 53, 931-935. https://doi.org/10.3345/kjp.2010.53.11.931</mixed-citation></ref><ref id="scirp.132068-ref19"><label>19</label><mixed-citation publication-type="other" xlink:type="simple">Sonia, S., Ferdous, E., Islam, M. and Rahman, S. (2023) Neutrophil Count, Platelet Indices, CRP and Their Association with Disease Activity of Juvenile Idiopathic Arthritis (JIA): A Study from Bangladesh. Open Journal of Rheumatology and Autoimmune Diseases, 13, 41-49. https://doi.org/10.4236/ojra.2023.131004</mixed-citation></ref><ref id="scirp.132068-ref20"><label>20</label><mixed-citation publication-type="other" xlink:type="simple">Albaker, A.R. (2020) Current Review of Systemic Juvenile Idiopathic Arthritis: What Do Paediatricians Need to Know? Open Journal of Pediatrics, 10, 769-801. https://doi.org/10.4236/ojped.2020.104078</mixed-citation></ref><ref id="scirp.132068-ref21"><label>21</label><mixed-citation publication-type="other" xlink:type="simple">Rajapaksa, G.K., Puvimanasinghe, J.P. and Padmasiri, E.A. (1995) Some Risk Factors of Rheumatoid Arthritis: A Case-Control Study. Master’s Thesis, University of Colombo, Sri Lanka.</mixed-citation></ref><ref id="scirp.132068-ref22"><label>22</label><mixed-citation publication-type="other" xlink:type="simple">Calabro, J.J. and Marchesano, J.M. (1968) The Early Natural History of Juvenile Rheumatoid Arthritis. Medical Clinics of North America, 52, 567-591. https://doi.org/10.1016/S0025-7125(16)32898-X</mixed-citation></ref><ref id="scirp.132068-ref23"><label>23</label><mixed-citation publication-type="other" xlink:type="simple">Rackham, O.J., Sills, J.A. and Davidson, J.E. (2002) Immunoglobulin Levels in Methotrexate Treated Paediatric Rheumatology Patients. Archives of Disease in Childhood, 87, 147-148. https://doi.org/10.1136/adc.87.2.147</mixed-citation></ref><ref id="scirp.132068-ref24"><label>24</label><mixed-citation publication-type="other" xlink:type="simple">Torre, I.D., Edwards, J. and Cambridge, G. (2012) Baseline Serum Immunoglobulin Levels in Patients with Rheumatoid Arthritis: Relationships with Clinical Parameters. Clinical and Experimental Rheumatology, 3, 1-12.</mixed-citation></ref><ref id="scirp.132068-ref25"><label>25</label><mixed-citation publication-type="other" xlink:type="simple">Davise, K., Stiehm, E.R., Woo, P. and Murray, K.J. (2001) Juvenile Idiopathic Polyarticular Arthritis and IgA Deficiency in the 22q11 Deletion Syndrome. The Journal of Rheumatology, 28, 2326-2334.</mixed-citation></ref><ref id="scirp.132068-ref26"><label>26</label><mixed-citation publication-type="other" xlink:type="simple">James, T., Cassidy, J.T., Petty, R.E. and Sullivan, D.B. (1973) Abnormalities in the Distribution of Serum Immunoglobulin Concentrations in Juvenile Rheumatoid Arthritis. Journal of Clinical Investigation, 52, 1931-1936. https://doi.org/10.1172/JCI107377</mixed-citation></ref></ref-list></back></article>